Pharmacokinetic-Pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements

CPT: Pharmacometrics and Systems Pharmacology

Volumn 1, Issue 1, 2012, Pages

  Pilla Reddy, V ^a   Petersson, K J ^b   Suleiman, A A ^b   Vermeulen, A ^c   Proost, J H ^a   Friberg, L E ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; JNJ 37822681; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EXPOSURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MODEL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; STEADY STATE;

EID: 84878762225     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.9     Document Type: Article

References (21)

1. Mueser, K.T. & McGurk, S.R. Schizophrenia. Lancet 363, 2063-2072 (2004
2. Seeman, P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci. Ther. 17, 118-132 (2011
3. Horacek, J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389-409 (2006
4. de Greef, R., Maloney, A., Olsson-Gisleskog, P., Schoemaker, J. & Panagides, J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 13, 121-130 (2011
5. Sernyak, M. & Rosenheck, R. Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications. Psychiatr. Serv. 58, 1292-1296 (2007
6. Rummel-Kluge, C. et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 38, 167-177 (2012
7. Matsui-Sakata, A., Ohtani, H. & Sawada, Y. Pharmacokinetic- pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab. Pharmacokinet. 20, 187-199 (2005
8. de Ridder, F., Vermeulen, A. Balancing efficacy and safety in the clinical development of an atypical antipsychotic, paliperidone extended-release. In: Clinical Trial Simulations: Applications and Trends (Kimko, Holly H. C., Peck Carl, C., eds). (Springer Science and Business Media, NY, 2011
9. Bergstrand, M., Söderlind, E., Weitschies, W. & Karlsson, M.O. Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Clin. Pharmacol. Ther. 86, 77-83 (2009
10. Te Beek, E.T., Moerland, M., de Boer, P.et al. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681. J Psychopharmacol. 26, 1119-1127 (2012
11. Lacroix, B.D., Sargentini-Maier, M.L., Karlsson, M.O., Friberg, L.E. Simultaneous modeling of the three ACR improvement thresholds - 20, 50 and 70% - in rheumatoid arthritis patients treated with certolizumab pegol. PAGE Abstr. 1811, (2010
12. Bizzotto, R., Zamuner, S., De Nicolao, G., Karlsson, M.O. & Gomeni, R. Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J. Pharmacokinet. Pharmacodyn. 37, 137-155 (2010
13. Snelder, N., Diack, C., Benson, N., Ploeger, B., Van der Graaf, P.H.A proposal for implementation of the Markov property into a continuous time transition state model in NONMEM. PAGE Abstr. 1536 (2009
14. Carlson, C.D., Cavazzoni, P.A., Berg, P.H., Wei, H., Beasley, C.M. & Kane, J.M. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: Comparisons with placebo, haloperidol, risperidone, or clozapine. J. Clin. Psychiatry 64, 898-906 (2003
15. NONMEM user's guide (1989-2009) [computer program]. Ellicott City, MD, USA: ICON Development Solutions, 2009.
16. Lindbom, L., Ribbing, J. & Jonsson, E.N. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75, 85-94 (2004
17. R: A language and environment for statistical computing. [computer program]. Vienna, Austria: R Foundation for Statistical Computing, 2010.
18. Samtani, M.N., Vermeulen, A. & Stuyckens, K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel oncemonthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 48, 585-600 (2009
19. Hoeben, E., Neyens, M., Mannaert, E., De Boer, P., Schmidt, M., Vermeulen, A. Population pharmacokinetic analysis of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. Abstr. 2069 PAGE. (2011
20. Nucci G., Gomeni R., Poggesi I. Model-based approaches to increase efficiency of drug development in schizophrenia: A can't miss opportunity. Expert Opin. Drug Discov. 4, 837-856 (2009
21. Te Beek E.T., de Boer P., Moerland M.,et al. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol. 26, 1128-1135 (2012